NOUS-209 Neoantigen Vaccine Shows Promise for Cancer Prevention in Lynch Syndrome Carriers
核心洞察
NOUS-209 demonstrated 100% immunogenicity in Lynch syndrome (搜索) carriers, with all evaluable participants developing robust T cell responses against frameshift peptide neoantigens (搜索) in a phase 1b/2 trial.
The vaccine showed a favorable safety profile with no treatment-related serious adverse events, while inducing durable immune responses that persisted for up to one year after vaccination.
Clinical evidence suggests potential efficacy, with no advanced adenomas (搜索) detected at end-of-study colonoscopies and a trend toward reduced microsatellite instability (搜索) in precancerous lesions.
A novel neoantigen vaccine has demonstrated promising safety and immunogenicity results in Lynch syndrome (搜索) carriers, offering new hope for cancer prevention in this high-risk hereditary population. The phase 1b/2 clinical trial of NOUS-209, published in Nature Medicine, represents a significant milestone in the emerging field of cancer interception.
Breakthrough Immunogenicity Results
The single-arm, open-label trial enrolled 45 healthy Lynch syndrome (搜索) carriers between November 2022 and November 2023. NOUS-209 achieved 100% immunogenicity in all 37 evaluable participants, with each developing interferon-γ T cell responses against the vaccine's 209 frameshift peptide neoantigens (搜索). The vaccine elicited an average of approximately 1,100 spot-forming cells at peak response, demonstrating robust immune activation.
"These findings highlight the strong potential of NOUS-209 as a cancer interception strategy for individuals with Lynch Syndrome (搜索)," said Eduardo Vilar-Sanchez, M.D., Ph.D., the study's principal investigator and Professor of Clinical Cancer Prevention at The University of Texas MD Anderson Cancer Center.
The immune responses proved both broad and durable. Participants showed reactivity against an average of eight different peptide pools, with 33% of participants demonstrating responses against 10-16 pools. Importantly, positive T cell responses remained detectable in 97% of participants at six months and 85% at one year, indicating sustained immune memory.
Favorable Safety Profile
NOUS-209 was administered as a prime-boost regimen, with an initial intramuscular injection of GAd20-209-FSPs (搜索) followed by MVA-209-FSPs (搜索) boost at week 8. The vaccine demonstrated an excellent safety profile, with 98% of participants reporting adverse events that were predominantly mild and transient.
No treatment-related serious adverse events occurred during the study. The most common side effects included injection-site reactions in 91% of participants after the prime dose and systemic symptoms such as fatigue (80%) and myalgia (76%). All grade 3 symptoms occurred after the prime dose only, lasted 1-4 days, and resolved completely without requiring hospitalization.
Functional Anti-Tumor Activity
Beyond demonstrating immune activation, the study provided compelling evidence of functional anti-tumor activity. Vaccine-induced CD8+ T cells showed direct cytotoxic capability against tumor cells expressing the targeted neoantigens. In laboratory experiments, T cells from vaccinated participants demonstrated significant tumor cell killing and increased apoptosis when co-cultured with cancer cells expressing the CDC7 (搜索) frameshift peptide.
The induced T cells acquired a terminally differentiated effector memory phenotype, indicating the development of long-term immune surveillance capacity. Flow cytometry analysis revealed that vaccine-specific CD8+ T cells expressed degranulation markers and secreted interferon-γ, confirming their cytotoxic function.
Clinical Evidence of Efficacy
While the trial was primarily designed to assess safety and immunogenicity, secondary endpoint analysis provided encouraging signals of clinical activity. At end-of-study colonoscopies, no participants had advanced adenomas (搜索), compared to two participants who had advanced adenomas at baseline. Advanced adenomas are considered direct precursors to colorectal cancer (搜索) and are more frequently associated with mismatch repair deficiency.
Genomic analysis of precancerous lesions revealed a trend toward reduced frequency of microsatellite instability (搜索) after vaccination. Specifically, microsatellite instability-high and microsatellite instability-low precancers decreased from 30% each at baseline to 17% and 8% respectively at study end.
Exploratory analysis showed an association between broader immune responses and reduced adenoma detection, with participants having no detectable adenomas showing responses against an average of four peptide pools compared to 1.5 pools in those with adenomas.
Addressing Unmet Medical Need
Lynch syndrome (搜索) affects approximately 1 in 300 individuals and significantly increases cancer risk, with carriers facing up to 80% lifetime risk of colorectal cancer (搜索) and elevated risks for endometrial, urothelial, and other cancers. Current management relies primarily on intensive screening and prophylactic surgery, approaches that detect rather than prevent cancer development.
"NOUS-209's ability to safely induce broad, potent, and durable immune responses against shared neoantigens is unique," said Elisa Scarselli, M.D., Chief Scientific Officer of Nouscom (搜索). "These data reinforce our confidence in NOUS-209's potential to intercept cancer before it develops in high-risk individuals with Lynch Syndrome (搜索)."
The vaccine targets 209 shared frameshift peptide neoantigens (搜索) that arise from mismatch repair deficiency characteristic of Lynch syndrome (搜索)-associated tumors. These neoantigens are foreign to the immune system and present in both precancerous and cancerous lesions, making them ideal targets for preventive immunotherapy.
Platform Innovation
NOUS-209 represents an off-the-shelf approach that contrasts with personalized neoantigen vaccines requiring individual tumor sequencing. The vaccine uses Nouscom (搜索)'s proprietary viral vector platform, employing heterologous prime-boost immunization with adenoviral and modified vaccinia Ankara vectors to deliver the 209 neoantigens totaling 6,000 amino acids.
This approach addresses practical limitations of personalized vaccines in the prevention setting, where bulk tumor tissue for sequencing is unavailable. By targeting recurrent shared antigens, the off-the-shelf strategy avoids the resource intensity and delays associated with personalized vaccine production.
Future Development
The Nature Medicine publication marks a significant milestone for both Nouscom (搜索) and the cancer interception field. "The publication of NOUS-209 data in Nature Medicine is a pivotal moment—not just for Nouscom, but for the future of cancer prevention," said Marina Udier, Ph.D., CEO of Nouscom.
The clinical trial was supported by the National Cancer Institute through the iCAN-PREVENT consortium, reflecting institutional commitment to cancer interception research. The data support advancing NOUS-209 into FDA- and EMA-aligned registration-enabling clinical trials for cancer interception in Lynch syndrome (搜索) carriers.
The study's limitations include its small sample size and predominantly white participant population, which may limit generalizability. Additionally, the trial was not powered to detect significant differences in advanced adenoma rates, though the observed reduction provides encouraging preliminary evidence.
These results establish NOUS-209 as a promising cancer interception strategy and validate the concept of using shared neoantigen vaccines for hereditary cancer prevention. The approach may have broader applications for other hereditary cancer syndromes characterized by specific mutational signatures.